Dr. Douglas S. Harrington, MD Fellow of the American Society of Preventive Cardiology, and the American Society of Clinical Pathology, who is an expert in laboratory diagnostic testing joins eHealth Radio and the Health Care and Health News Channels. Dr. Harrington is also the Chairman of the GUARDaHEART Foundation 501(c)3 who is actively partnering with community organizations, nonprofit organizations, businesses, and city officials to provide the community with No-Cost COVID-19 Antibody Tests covered under the CARES Act.
Listen to interview with host Eric Michaels and guest Dr. Douglas S. Harrington discuss the following:
- What is GUARDaHEART Foundation’s goal in partnering with the community to provide the SARS-CoV-2 Antibody Test?
- What is the difference between a COVID-19 swab test vs and COVID-19 SARS-CoV-2 antibody test?
- Who should take the antibody test and what are the benefits of having the test?
- What is the difference between IgG and IgM antibodies and how long does it take to develop antibodies?
- How long do the antibodies stay in my body?
- If my antibody report results positive, am I immune to COVID-19?
- What happens if someone tests positive for the COVID-19 Antibodies? Should they be quarantined?
- Is it true that the Latin Community and African American Community have the highest rates of COVID? If so, why is that?
- What is the correlation of heart disease and coronavirus?
- Tell us about the SARS-CoV-2 serology antibody test being provided with a sensitivity of 100% and a specificity of 99.6% based on initial performance evaluations. Is this more reliable than other tests being provided?
- Are there natural medicines that aim to help to reduce an individual from getting the virus?
Dr. Douglas Harrington has over 25 years of experience in the research, development, commercialization, and expansion of innovative healthcare technology and services. Dr. Harrington was a member of one of the first heart transplant teams led by Dr. Jack Copeland from Stanford University. Heco-founded one of the first clinical molecular biology laboratories in the U.S. with the Nebraska Lymphoma StudyGroup headed by Dr. Jim Armitage. As President and Lab Director of Nichols Institute, Dr. Harrington expanded their molecular genetics, infectious disease, immunology,cytogenetic, and anatomic pathology offerings. Dr. Harrington led the team that developed one of the first digital microscopes targeted at minimal residual disease and circulating tumor cells as the founder and CEO of Clarient. Dr.Harrington also led the turnaround and reinstatement of theFederal license of Specialty Laboratories, a New York StockExchange company, as CEO and Laboratory Director.
Dr. Harrington has developed patents for an automated method for image analysis of residual cancer cells, a patent covering catalytic heavy metal extraction, and a patent pending on biomarker assay for diagnosis and classification of cardiac disease. He has been involved as director or founder of multiple startup companies - from devices to molecular genetics focusing on immunology, cancer and cardiology,where he has taken a number of new molecular technologies through state and federal regulatory approval, and has been involved in the commercialization of over 200 academic discoveries. He is a member of Phi Beta Kappa, the nation’s most prestigious academic honor society.
Dr. Harrington is the inventor of the PULS Cardiac Test (TM) ,a breakthrough blood test for the detection of the leading cause of heart attacks, and CEO & Laboratory Director ofGlobal Discovery Biosciences. Throughout his career Dr.Harrington has remained a Clinical Professor of Pathology at the USC Keck School of medicine, a published author of numerous peer-reviewed papers, and a sought after speaker in the area of preventive medicine and technology development. Dr. Harrington received his BA in molecular biology, his MD from the University of Colorado HealthSciences Center, and is a board-certified in hematology,anatomic and clinical pathology.